We used LysM-Cre (Lyz2-Cre) to express Cdx2 in GMP and terminally differentiated myeloid cells, but not HSCs to test whether Cdx2 expression in only myeloid cells is sufficient for AML (Fig. 4a). The gene discussed is CDX2; the disease is acute myeloid leukemia.